Tokayev was briefed on Kazakhstan’s coronavirus vaccine development
courtesy of RK President’s press service
President Kassym-Jomart Tokayev received the director general of the Scientific Research Institute for Biological Safety Problems Kunsulu Zakariya, Kazpravda.kz refers to the Akorda press service reporting.
Tokayev was briefed on development progress of domestic vaccine against coronavirus.
According to Kunsulu Zakariya, on the basis of the institute, work is underway on five platforms to create vaccines against COVID-19. The inactivated vaccine developed by the institute was approved by the World Health Organization and passed the first stage of clinical trials. Currently, the second stage of the study is being carried out at the National Research Center for Phthisiopulmonology.
The second currently developed domestic split vaccine against coronavirus infection has been approved by the WHO and successfully passed clinical trials. Materials for this vaccine are in the National Center for Expertise of Medicines and Medical Devices.
Construction of domestic immune drugs production on the territory of the Research Institute is slated. The design capacity of the plant is to be 60 million doses of vaccines per year.
The President supported the proposal to increase the volume of housing construction for the Institute employees. The meeting also discussed issues of increasing the salaries of scientists, attracting young specialists, as well as introducing the concept of "temporary registration of a vaccine" into regulatory legal acts.
The President gave specific instructions on the development of domestic vaccines.